Chemotherapy for advanced gastric cancer: across the years for a standard of care (Q34617795)

3 August 2017

1 reference

title

Chemotherapy for advanced gastric cancer: across the years for a standard of care (English)

1 reference

3 August 2017

1 reference

Rossana Berardi

4

0 references

Stefano Cascinu

object named as

Stefano Cascinu

7

0 references

author name string

Mario Scartozzi

1

1 reference

3 August 2017

Eva Galizia

2

1 reference

3 August 2017

Lorena Verdecchia

3

1 reference

3 August 2017

Stefania Antognoli

5

1 reference

3 August 2017

Silvia Chiorrini

6

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

797-808

1 reference

Evolving chemotherapy for advanced gastric cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Palliative chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.6.797

21 January 2018

Identifiers

DOI

10.1517/14656566.8.6.797

1 reference

release_bkwzqt3i7vhu3glgbwkswwwt5e

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bkwzqt3i7vhu3glgbwkswwwt5e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference